MFN cuts manufacturer drug prices, but greater transparency across PBMs and pharmacies is needed to ensure those savings reach patients, writes Paul Pruitt.
Outsourced clinical trials risk safety missteps when communication falters. Learn how a clear, detailed data-flow process affects your safety decisions.
Though rescue studies are common, there are ample tactics to avoid these situations altogether, including robust planning, data analysis, and prioritization of patient recruitment and retention.
Equipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
Identifying manufacturing capacity that can adapt to a growing and changing biopharma landscape requires an emphasis on technical and operational expertise combined with agility and flexibility.
Solvent recovery can reduce waste, but scaling it brings technical and regulatory risks. See how three approaches performed and what it takes to move from bench to commercial scale.
